Discovery and validation of genetic markers to establish effective indications of anti-osteoporotic drugs
Not Applicable
Recruiting
- Conditions
- Diseases of the musculo-skeletal system and connective tissue
- Registration Number
- KCT0000426
- Lead Sponsor
- Asan Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 6604
Inclusion Criteria
Patients who visit Asan Medical Center for osteoporosis and give the informed consent.
Patients with measurement of bone mineral density (BMD) for osteoporosis (Classification of case / control group by BMD result)
Wahout peroid: Two years using agents more than 6 months against osteoporosis
Exclusion Criteria
1. Subjects within wash-out period
2. Secondary osteoporosis: Disorders strongly associated with osteoporosis. These include rheumatoid arthritis, untreated long-standing hyperthyroidism or Graves' disease, chronic liver disease, hyperparathyroidism, and parathyroid adenoma
3. Other conditions were not suitable in cohort study: Chronic renal failure, active malignany, and transplantation
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Association between novel discovered SNP with osteoporosis or osteoporotic fracture risk
- Secondary Outcome Measures
Name Time Method Association between novel discovered SNP with bone mineral density ;Association between novel discovered SNP with changes of bone mineral density ;Effect of novel discovered SNP on changes of bone mineral density according to treatment methods